Bank Of Nova Scotia Seagen Inc. Transaction History

Bank Of Nova Scotia

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $15.6 Million - $17.6 Million	-81,385 Reduced 53.59%	70,469 $14.9 Million
Q2 2023 Aug 03, 2023	BUY	$187.64 - $206.25 $27.5 Million - $30.3 Million	146,676 Added 2832.68%	151,854 $29.2 Million
Q1 2023 May 11, 2023	SELL	$127.59 - $203.08 $18.6 Million - $29.5 Million	-145,413 Reduced 96.56%	5,178 $1.05 Million
Q4 2022 Feb 09, 2023	BUY	$117.37 - $139.17 $4.93 Million - $5.85 Million	42,018 Added 38.7%	150,591 $19.4 Million
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $14 Million - $18.6 Million	103,382 Added 1991.56%	108,573 $14.9 Million

Q2 2022 Aug 08, 2022	BUY	$108.81 - $179.33 $564,832 - $930,902	5,191 New	5,191 $918,000
Q2 2022 Aug 05, 2022	SELL	$108.81 - $179.33 $930,107 - $1.53 Million	-8,548 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$119.61 - $157.85 $749,476 - $989,088	6,266 Added 274.58%	8,548 $1.23 Million
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $20.3 Million - $27.2 Million	-142,718 Reduced 98.43%	2,282 $353,000
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $155,982 - $185,952	-1,095 Reduced 0.75%	145,000 $24.6 Million
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $19.7 Million - $23.5 Million	146,095 New	146,095 $23.1 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.